There are few moments in recent memory that have stopped people mid-scroll the way a two-minute video from a small Alabama community did in late April 2026. It wasn’t a celebrity. It wasn’t breaking political news. It was a 15-year-old boy, sitting with his mom’s phone, speaking plainly about what it’s like to know you might be dying. He wasn’t performing. He wasn’t scripted. He just talked, the way kids from the rural South talk, with a directness that cut through everything. And somehow, that honesty did something that weeks of his family’s efforts behind the scenes couldn’t manage. It changed everything.
Will Roberts lives in Ralph, Alabama, an unincorporated community in Tuscaloosa County that most people have never heard of. By any measure, his situation is one of the hardest a family can face. He was diagnosed with osteosarcoma in January 2025. The aggressive bone cancer has spread throughout his body, and he has already lost half of one leg to the disease. Chemotherapy, the standard first line of defense, had stopped working. His family had been fighting for answers, making calls, trying to reach anyone who might help, for over a week. Nothing was moving. Then Will picked up his mom’s phone.
What he did next wasn’t planned. He filmed a two-minute video on his mom’s Facebook page without his parents knowing. He told viewers who he was, what was happening to his body, and what he needed. He asked them to share it. That video would eventually be viewed more than three million times, and within 24 hours, it would reach U.S. senators, a country music legend, and the country’s top health official. His father, Jason, said: “What we failed to do in a week, he has done literally in a few hours.”
What Osteosarcoma Is and Why Stage 4 Is So Difficult
To understand why Will’s situation is so serious, you need to know a little about what he’s up against. Osteosarcoma is a type of sarcoma and the most common type of bone cancer. Each year, about 1,000 new cases are diagnosed in the United States, and about half of those are in children and adolescents. Most cases occur in children, teens, and young adults between the ages of 10 and 30, with teens being the most affected age group.
The cancer most often starts near growth plates in the long bones of the legs or arms, which is why it tends to strike during the rapid growth years of adolescence. Doctors typically treat it with a combination of surgery and multi-drug chemotherapy. When caught early and localized to one area, there is a real chance of survival. For people with localized osteosarcoma that hasn’t spread, survival rates range from 60 to 75 percent. But when the cancer metastasizes, meaning it spreads to other parts of the body, those numbers fall sharply. For osteosarcoma that has spread when it is found, survival rates range from just 5 to 30 percent, according to the American Cancer Society.
Compounding the challenge is a treatment landscape that hasn’t moved as fast as patients need it to. The five-year overall survival rate for children and adolescents with osteosarcoma has essentially been stuck on a plateau for the last 30 years, according to a 2024 meta-analysis published in Cancer Epidemiology. For kids like Will, who have exhausted the standard options and seen their disease keep advancing, that stagnation is devastating in the most personal possible way.
One Boy’s Video, One Specific Request
In the video, Will spoke with raw honesty about the state of his illness. “It’s a very, very, very deadly and very hard to treat bone cancer, and my chemos are just not working,” he said. “We’ve tried basically everything there is, and we’re getting towards the end of the road.”
His request wasn’t vague. Will was asking specifically for access to an experimental drug called DeltaRex-G, which his parents had been researching as a potential option. He asked viewers to share his message as widely as possible, including to the highest levels of government. Despite knowing the odds, he also made clear that his motivations went beyond himself. “Even if it’s too late for me and I can’t get the medicine that I’m wanting, I know I can help hundreds of other kids who have my specific cancer or pancreatic cancer, different cancers like that,” he said.
That level of selflessness, from a 15-year-old facing a terminal prognosis, is what made the video impossible to look away from. It also helped explain why the response was so fast and so sweeping.
Will’s mother, Brittney Battles Roberts, publicly credited several individuals who helped move the effort forward, including Congressman Barry Moore, musician Hank Williams Jr. and his wife Brandi, and Senators Katie Britt and Tommy Tuberville. Most significantly, Dr. Oz personally reached out to Will’s family and contacted the developers of DeltaRex-G in Santa Monica, California. Telehealth calls happened immediately, and the family began preparing to travel west for treatment.
Read More: Experimental Cancer Treatment Destroys Cancer Cells Without Using Any Drugs
What DeltaRex-G Actually Is
DeltaRex-G is not a mainstream drug. It’s not something you’ll find at a typical oncology center, and it’s not currently approved as a standard treatment in the United States. Understanding what it is, and what it isn’t, matters.
DeltaRex-G is an experimental gene therapy designed to target and destroy cancer cells by delivering a genetic agent that disrupts tumor growth. The treatment has been studied in early-stage clinical trials and limited expanded access programs for patients with advanced, treatment-resistant cancers, including osteosarcoma. While some studies have shown signs of tumor response in certain patients, the therapy remains investigational and is not widely approved as a standard treatment.
The science behind it is worth understanding at a basic level. DeltaRex-G works by delivering a retroviral vector, a specially engineered carrier molecule, to tumor cells. That carrier encodes for a construct designed to inhibit the cyclin G1 gene (CCNG1), which leads to cancer cell death. In plain terms, it’s a gene therapy that seeks out abnormal, fast-dividing tumor cells and instructs them to stop growing. DeltaRex-G is designed to kill not only proliferating cancer cells but also the supporting tissue and blood supply that feeds the tumor, and it may also help prime the tumor to respond better to other therapies.
DeltaRex-G has been tested in over 280 cancer patients worldwide in Phase 1 and Phase 2 studies, with some participants showing long-term survivorship of more than 10 years in cases involving metastatic cancer including osteosarcoma, soft tissue sarcoma, breast cancer, and B-cell lymphoma. A 2024 paper in Anticancer Research reported that in a Phase 2 study using DeltaRex-G specifically for chemo-resistant metastatic osteosarcoma, there were 4 partial responses and 8 cases of stable disease among 17 evaluable patients, for an overall response rate of 23.5 percent and a disease control rate of 70.6 percent, with only mild side effects reported.
DeltaRex-G gained FDA orphan drug status for osteosarcoma and soft tissue sarcoma in the USA in 2009. Orphan drug status is a designation the FDA grants to treatments targeting rare diseases, giving developers incentives like tax credits and faster review. It signals that regulators recognize the potential of the therapy, even if broader approval hasn’t followed. The drug has also received expanded access authorization, allowing eligible patients who are out of standard options to receive it outside of a formal trial. That expanded access program has been available for eligible patients aged 12 and older for sarcoma cases.
Will, at 15, meets that threshold. His family, after weeks of hitting walls through conventional channels, watched a two-minute Facebook video open those doors in less than a day.
The Role of Expanded Access in Cases Like Will’s
What happened for Will Roberts isn’t unique in concept, even if the speed and scale of public attention was remarkable. The FDA’s expanded access pathway, sometimes called “compassionate use,” exists specifically for situations like his: patients with a serious or life-threatening condition who have no remaining standard treatment options and who want access to an experimental therapy that isn’t yet fully approved.
Getting approved for expanded access typically requires a physician to make a formal request to the FDA and to the drug’s developer. The process can move quickly in urgent cases, but it usually doesn’t happen in 24 hours without significant outside pressure. That’s where Will’s video, and the chain of events it set off, made a concrete difference. According to a report from Yellowhammer News, the family received a call from Dr. Mehmet Oz, who then reached out to the developers of DeltaRex-G. “We have now had a telehealth call with the doctors, and they told us that Will is gaining access to the drug and we will be traveling to Santa Monica very soon,” the family posted.
Brittney Roberts described the rapid developments as overwhelming, saying the momentum began with her son’s decision to speak out on his own. “This started with a 15-year-old who refused to stay quiet,” she wrote.
For parents of children with rare or treatment-resistant cancers, Will’s story illustrates both the potential and the reality of how access to experimental medicine currently works in the United States. The science may exist. The clinical trial data may be promising. But access often depends on who you can reach and how loudly you can advocate. That’s a system question that goes beyond any single teenager’s story.
What This Means for You
If you or someone you love is navigating a cancer diagnosis, especially one involving a rare cancer where standard treatments have stopped working, Will’s story carries some practical lessons.
First, expanded access programs are real and they are worth pursuing. The FDA maintains an expanded access program that allows patients to apply for access to investigational drugs outside of clinical trials. Your oncologist can initiate this process, and patient advocacy organizations can often help navigate it. Clinical trials and expanded access programs may offer access to new treatments when standard options are exhausted.
Second, advocacy matters at every level. Will’s family spent over a week working through official channels with little result. When their son told his story directly, in his own words, to whoever would listen, the phone started ringing within hours. That doesn’t mean every family should turn to social media in a health crisis. But it does mean that persistence, visibility, and knowing how to communicate clearly can sometimes open doors that formal processes keep closed.
As for Will, his story is far from over. He is heading to California with his family, carrying a diagnosis that is still terrifyingly serious, but also carrying something he didn’t have before his video went live: a chance. While he remains in a battle for his life, he has said he is thinking about others, and that even if his outcome is uncertain, he wants other kids facing the same disease to have a better shot than he did. That instinct, to fight for yourself and simultaneously for the next kid in the same position, is the thread running through everything Will Roberts has done. It’s worth paying attention to.
AI Disclaimer: This article was created with the assistance of AI tools and reviewed by a human editor.
Read More: Deadly Brain Tumor Disappears After Experimental Cancer Treatment